AMNEAL PHARMACEUTICALS, INC. Operating Cash Flow
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Operating Cash Flow of -$47.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$21.24M, a 125.35% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$26.74M, a 461.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $130.31M, a 10.36% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $118.45M, a 16.45% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $339.99M, a 15.21% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was $295.10M, a 14.61% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was $345.58M, a 430.84% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was $65.10M, a 73.08% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$21.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$47.99M 10-Q · filed 2026-08-06 | $82.33M derived: sum of 3 quarters · filed 2026-08-06 | $200.78M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$26.74M 10-Q · filed 2026-05-07 | $103.57M derived: sum of 2 quarters · filed 2026-05-07 | $222.02M derived: sum of 3 quarters · filed 2026-05-07 | $305.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $130.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $248.76M derived: sum of 2 quarters · filed 2026-02-27 | $332.58M derived: sum of 3 quarters · filed 2026-08-06 | $339.99M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $118.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $202.27M derived: sum of 2 quarters · filed 2026-08-06 | $209.68M 10-Q · filed 2025-11-06 | $327.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $83.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $91.23M 10-Q · filed 2026-08-06 | $209.31M derived: sum of 3 quarters · filed 2026-08-06 | $351.08M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $7.41M 10-Q · filed 2026-05-07 | $125.49M derived: sum of 2 quarters · filed 2026-05-07 | $267.26M derived: sum of 3 quarters · filed 2026-05-07 | $306.92M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $118.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $259.85M derived: sum of 2 quarters · filed 2026-02-27 | $299.51M derived: sum of 3 quarters · filed 2026-02-27 | $295.10M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $141.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $181.43M derived: sum of 2 quarters · filed 2025-11-06 | $177.02M 10-Q · filed 2025-11-06 | $312.84M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $39.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $35.25M 10-Q · filed 2025-08-07 | $171.07M derived: sum of 3 quarters · filed 2026-02-27 | $252.46M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | -$4.41M 10-Q · filed 2025-05-07 | $131.41M derived: sum of 2 quarters · filed 2026-02-27 | $212.80M derived: sum of 3 quarters · filed 2026-02-27 | $201.46M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $135.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $217.21M derived: sum of 2 quarters · filed 2026-02-27 | $205.87M derived: sum of 3 quarters · filed 2026-02-27 | $345.58M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $81.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $70.04M derived: sum of 2 quarters · filed 2024-11-12 | $209.75M 10-Q · filed 2024-11-12 | $186.46M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | -$11.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $128.37M 10-Q · filed 2024-08-09 | $105.08M derived: sum of 3 quarters · filed 2025-02-28 | $198.65M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $139.71M 10-Q · filed 2024-05-08 | $116.42M derived: sum of 2 quarters · filed 2025-02-28 | $209.99M derived: sum of 3 quarters · filed 2025-02-28 | $84.47M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | -$23.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $70.28M derived: sum of 2 quarters · filed 2025-02-28 | -$55.24M derived: sum of 3 quarters · filed 2025-02-28 | $65.10M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $93.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$31.95M derived: sum of 2 quarters · filed 2023-11-09 | $88.39M 10-Q · filed 2023-11-09 | $151.65M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | -$125.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$5.18M 10-Q · filed 2023-08-08 | $58.08M derived: sum of 3 quarters · filed 2024-03-14 | $140.45M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $120.34M 10-Q · filed 2023-05-09 | $183.60M derived: sum of 2 quarters · filed 2024-03-14 | $265.97M derived: sum of 3 quarters · filed 2024-03-14 | $214.03M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $63.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $145.63M derived: sum of 2 quarters · filed 2024-03-14 | $93.69M derived: sum of 3 quarters · filed 2024-03-14 | $241.82M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $82.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $30.43M derived: sum of 2 quarters · filed 2022-11-07 | $178.56M 10-Q · filed 2022-11-07 | $284.52M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-06-30 | -$51.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $96.19M 10-Q · filed 2022-08-08 | $202.15M derived: sum of 3 quarters · filed 2023-03-03 | $246.93M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-03-31 | $148.13M 10-Q · filed 2022-05-06 | $254.09M derived: sum of 2 quarters · filed 2023-03-03 | $298.86M derived: sum of 3 quarters · filed 2023-03-03 | $478.10M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2020-12-31 | $105.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $150.73M derived: sum of 2 quarters · filed 2023-03-03 | $329.98M derived: sum of 3 quarters · filed 2023-03-03 | $379.00M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $44.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $224.02M derived: sum of 2 quarters · filed 2021-11-08 | $273.04M 10-Q · filed 2021-11-08 | $222.15M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $179.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $228.27M 10-Q · filed 2021-08-09 | $177.38M derived: sum of 3 quarters · filed 2022-03-01 | $317.29M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $49.03M 10-Q · filed 2021-05-07 | -$1.86M derived: sum of 2 quarters · filed 2022-03-01 | $138.05M derived: sum of 3 quarters · filed 2022-03-01 | $159.14M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$50.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $89.02M derived: sum of 2 quarters · filed 2022-03-01 | $110.11M derived: sum of 3 quarters · filed 2022-03-01 | $1.71M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $139.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $161.00M derived: sum of 2 quarters · filed 2020-11-06 | $52.59M 10-Q · filed 2020-11-06 | $312.25M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $21.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$87.32M 10-Q · filed 2020-08-06 | $172.34M derived: sum of 3 quarters · filed 2021-03-01 | $234.46M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | -$108.41M 10-Q · filed 2020-05-11 | $151.24M derived: sum of 2 quarters · filed 2021-03-01 | $213.37M derived: sum of 3 quarters · filed 2021-03-01 | $114.79M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $259.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $321.78M derived: sum of 2 quarters · filed 2021-03-01 | $223.20M derived: sum of 3 quarters · filed 2021-03-01 | $250.23M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $62.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$36.45M derived: sum of 2 quarters · filed 2019-11-07 | -$9.42M 10-Q · filed 2019-11-07 | -$9.42M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | -$98.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$71.55M 10-Q · filed 2019-08-05 | -$71.55M derived: sum of 3 quarters · filed 2019-08-05 | $1.96M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2018-03-31 | $27.03M 10-Q · filed 2019-05-09 | $0.00 10-Q · filed 2018-05-15 | $27.03M derived: sum of 2 quarters · filed 2019-05-09 | $100.54M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $0.00 10-K · filed 2018-03-09 | $73.51M derived: sum of 2 quarters · filed 2018-11-07 | $234.19M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $73.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $168.92M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $95.41M 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | $115.06M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |